Literature DB >> 24365176

Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy.

Akiko Miki1, Naoshi Kondo2, Suiho Yanagisawa1, Hiroaki Bessho1, Shigeru Honda1, Akira Negi1.   

Abstract

PURPOSE: To investigate whether complement factor H (CFH) gene DNA variants are associated with central serous chorioretinopathy (CSCR).
DESIGN: Cross-sectional study. PARTICIPANTS: A case-control group of 140 CSCR subjects and 2 different control groups: 934 population-based controls and 335 hospital-based controls.
METHODS: Five single-nucleotide polymorphisms (SNPs) in CFH (rs3753394, rs800292, rs2284664, rs1329428, and rs106548) were evaluated for association with CSCR in 2 separate association analyses comparing CSCR subjects with 2 different control groups. Genotyping was performed using TaqMan technology (Applied Biosystems, Foster City, CA). MAIN OUTCOME MEASURES: Allele and haplotype frequencies of the 5 variants in the CFH region.
RESULTS: Highly statistically significant associations with CSCR were found for the 5 SNPs. The strongest association was observed with rs1329428 (allelic P = 6.44×10(-6); odds ratio, 1.79; 95% confidence interval [CI], 1.39-2.31, cases vs. population-based controls), which accounted for 35.5% of the population-attributable fraction for CSCR. Consistent with the analysis, rs1329428 showed the strongest disease association (allelic P = 1.00×10(-5); odds ratio, 1.89; 95% CI, 1.42-2.50) in comparing cases with hospital-based controls. The second most strongly associated SNP, rs1065489, was correlated highly with the most strongly associated SNP, rs1329428 (r(2) = 0.77), and their effects could not be distinguished statistically from each other. A conditional logistic regression analysis revealed that the 2 highly correlated SNPs, rs1329428 and rs1065489, account for the association signals detected at the CFH locus.
CONCLUSIONS: We identified a novel association between CSCR and common CFH polymorphisms. Our findings support the involvement of CFH in the pathogenesis of CSCR; exploration of the role of CFH could yield important insights into the biological mechanisms underlying CSCR. Our identification of common CFH variants as susceptibility elements for CSCR will open new avenues for research, leading to a better understanding of CSCR pathogenesis and ultimately to the development of improved therapeutic approaches.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24365176     DOI: 10.1016/j.ophtha.2013.11.020

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  40 in total

1.  Association between CFH single nucleotide polymorphisms and response to photodynamic therapy in patients with central serous chorioretinopathy.

Authors:  Dandan Linghu; Hui Xu; Zhiqiao Liang; Tingting Gao; Zhaojun Lin; Xiaoxin Li; Lvzhen Huang; Mingwei Zhao
Journal:  Int Ophthalmol       Date:  2020-01-10       Impact factor: 2.031

2.  Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy.

Authors:  Elon H C van Dijk; Rosa L Schellevis; Maaike G J M van Bergen; Myrte B Breukink; Lebriz Altay; Paula Scholz; Sascha Fauser; Onno C Meijer; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon; Eiko K de Jong
Journal:  JAMA Ophthalmol       Date:  2017-05-01       Impact factor: 7.389

3.  A novel mutation of sgk-1 gene in central serous chorioretinopathy.

Authors:  Mahmut Akyol; Muhammet Kazım Erol; Ozdemir Ozdemir; Deniz Turgut Coban; Ahmet Burak Bilgin; Esin Sogutlu Sari; Elif Betul Turkoglu
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

4.  Imaging characteristics of bilateral CSCR cases:12 months follow up.

Authors:  Sumit Randhir Singh; Deepika C Parameswarappa; Supriya Arora; Dmitrii S Maltsev; Niroj Kumar Sahoo; Alexei N Kulikov; Claudio Iovino; Filippo Tatti; Ramesh Venkatesh; Nikitha Gurram Reddy; Ram Snehith Pulipaka; Enrico Peiretti; Jay Chhablani
Journal:  Eye (Lond)       Date:  2022-01-13       Impact factor: 3.775

5.  Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study.

Authors:  Rosa L Schellevis; Elon H C van Dijk; Myrte B Breukink; Lebriz Altay; Bjorn Bakker; Bobby P C Koeleman; Lambertus A Kiemeney; Dorine W Swinkels; Jan E E Keunen; Sascha Fauser; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon; Eiko K de Jong
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

6.  Relationship between mean platelet volume and central serous chorioretinopathy.

Authors:  Ayhan Dursun; Mustafa Ilker Toker; Ayşe Vural Ozec; Erman Bozali; Kadir Kirboga; Feyza Gulac Dursun; Haydar Erdogan; Aysen Topalkara; Mustafa Kemal Arici
Journal:  Int Ophthalmol       Date:  2016-04-25       Impact factor: 2.031

7.  CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY.

Authors:  Alexandre Matet; Suzanne Yzer; Emily Y Chew; Alejandra Daruich; Francine Behar-Cohen; Richard F Spaide
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

Review 8.  Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.

Authors:  Francesco Sartini; Michele Figus; Marco Nardi; Giamberto Casini; Chiara Posarelli
Journal:  Eye (Lond)       Date:  2019-03-01       Impact factor: 3.775

Review 9.  [Central serous chorioretinopathy].

Authors:  Laurenz Pauleikhoff; Hansjürgen Agostini; Clemens Lange
Journal:  Ophthalmologe       Date:  2021-04-16       Impact factor: 1.059

10.  Association of central serous chorioretinopathy with single nucleotide polymorphisms in complement factor H gene in Iranian population.

Authors:  Reza Karkhaneh; Mohsen Toufighi; Akbar Amirfiroozy; Aliasghar Ahmad-Raji; Oveis Ahmadzadeh; Alborz Mahdavi; Morteza Naderan
Journal:  Eye (Lond)       Date:  2021-05-11       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.